TSPO and glioblastoma: Patients with glioblastoma and short survival showed higher TSPO-PET signals in the contralateral hemisphere (≤11.2 months median survival: SUVr 0.964 ± 0.144) compared to patients with longer survival (>11.2 months median survival: SUVr 0.847 ± 0.093, F1,29 = 7.14, P = 0.012; Fig. 3E), also after adjustment for age, sex, the TSPO SNP, and initiation of glucocorticoid medication prior to PET as covariates (F1,25 = 7.01, P = 0.014).